Financial Results
Q3 2025 – coming soon!
Fresenius will publish its Q3 2025 results on November 5, 2025. The conference call will take place at 1:30 pm (CET). Please see below for the dial-in details for the webcast.
As a service to investors and sell-side analysts, we are providing an Aide Memoire ahead of Fresenius quiet period which began on October 24, 2025. This document includes a summary of relevant information that Fresenius has communicated previously or made publicly available to the capital market or otherwise. The Aide Memoire may prove helpful in assessing Fresenius’ financial performance ahead of the publication of its Q3/25 financial results on November 5, 2025.
Q3/25 Results
WebcastDocuments
Q3/25 Aide Memoire (PDF)Selected Key Figures Q2/2025
GROUP REVENUE 1
€ 5571 m
+ 5% 2
Q2/24: €5,414 m
GROUP EBIT 1
€ 654 m
+0% 3
Q2/24: €660 m
NET INCOME 1, 4
€ 412 m
+8% 3
Q2/24: €388 m
EPS 1, 4
€ 0.73
+8% 3
Q2/24: €0.69
1 Before special items
2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
3 Growth rate at constant currency (cc) and adjusted for Argentina hyperinflation
4 Excluding Fresenius Medical Care
Revenue by business segment
| € in millions | Q2/25 | Q2/24 | Growth at actual rates | Growth at constant rates | Organic growth1 | Acquisitions/Divestitures | % of total revenue |
|---|---|---|---|---|---|---|---|
Fresenius Kabi | 2,111 | 2,101 | 0% | 5% | 6%1 | -1% | 38% |
Fresenius Helios | 3,370 | 3,230 | 4% | 5% | 5% | 0% | 60% |
Total | 5,571 | 5,414 | 3% | 5% | 5% | 0% | 100%2 |
-
1 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation
2 Remaining 2% Corporate/Other revenue
Before special items